Literature DB >> 17949899

Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM).

Najmunnisa Nasreen1, Kamal A Mohammed, Yimu Lai, Veena B Antony.   

Abstract

The objective of this study was to understand the possible mechanisms of activation of receptor EphA2 by its ligand ephrinA1 in malignant mesothelioma cell (MMC) growth. Activation of receptor EphA2 by its ligand ephrinA1 triggered the phosphorylation of EphA2. Ligand activation of EphA2 also induced phosphorylation of ERK1/2 and significantly decreased MMC proliferation. Ligand activated and ephrinA1 vector (pcDNA/EFNA1) transfected MMC demonstrated decreased clonal growth in 3-D matrigels when compared to resting MMC. These studies suggest that EphA2 activation by its ligand ephrinA1 transmits intracellular signals from cell membrane to nucleus via ERK1/2 signaling cascade and inhibits MM growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949899     DOI: 10.1016/j.canlet.2007.09.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  The SAM domain inhibits EphA2 interactions in the plasma membrane.

Authors:  Deo R Singh; Fozia Ahmed; Michael D Paul; Manasee Gedam; Elena B Pasquale; Kalina Hristova
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-10-21       Impact factor: 4.739

2.  EphA2 targeted intratumoral therapy for non-small cell lung cancer using albumin mesospheres.

Authors:  Hung-Yen Lee; Kamal A Mohammed; Fredric Kaye; Brij M Moudgil; Najmunnisa Nasreen
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 3.  Eph- and ephrin-dependent mechanisms in tumor and stem cell dynamics.

Authors:  Erika Gucciardo; Nami Sugiyama; Kaisa Lehti
Journal:  Cell Mol Life Sci       Date:  2014-05-04       Impact factor: 9.261

4.  Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner.

Authors:  Hea Nam Hong; You Jin Won; Ju Hee Shim; Hyun Ji Kim; Seung Hee Han; Byung Sik Kim; Hee Sung Kim
Journal:  J Cancer Res Clin Oncol       Date:  2018-06-12       Impact factor: 4.553

5.  Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.

Authors:  Najmunnisa Nasreen; Nazli Khodayari; Kamal A Mohammed
Journal:  Am J Cancer Res       Date:  2012-02-15       Impact factor: 6.166

Review 6.  Ephs and ephrins in cancer: ephrin-A1 signalling.

Authors:  Amanda Beauchamp; Waldemar Debinski
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

Review 7.  Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Authors:  D Marquez-Medina; S Popat
Journal:  Clin Transl Oncol       Date:  2015-12-17       Impact factor: 3.405

Review 8.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

9.  EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling.

Authors:  Deo R Singh; Fozia Ahmed; Christopher King; Nisha Gupta; Matt Salotto; Elena B Pasquale; Kalina Hristova
Journal:  J Biol Chem       Date:  2015-09-11       Impact factor: 5.157

10.  A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.

Authors:  Deo R Singh; Elena B Pasquale; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2016-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.